Autolus Therapeutics (AUTL) Non-Current Assets (2017 - 2026)
Autolus Therapeutics' (AUTL) quarterly Non-Current Assets came in at $153.2 million in Q4 2025, up 25.75% YoY from $121.8 million in Q4 2024, and up 3.92% on a QoQ basis from $147.4 million in Q3 2025.
Autolus Therapeutics (AUTL) Non-Current Assets (2017 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of Non-Current Assets data on file, last reported at $153.2 million in Q4 2025.
- Quarterly Non-Current Assets rose 25.75% year-over-year to $153.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $577.8 million (up 36.49% YoY) and the FY2025 annual result came in at $153.2 million, up 25.75% from the prior year.
- Non-Current Assets advanced to $153.2 million in Q4 2025, from $147.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $153.2 million in Q4 2025 to a low of $2.5 million in Q3 2021.
- A 5-year average of $82.7 million and a median of $95.3 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets dropped 13.08% — and 2022, when it jumped 1950.92%.
- Tracing AUTL's Non-Current Assets over 5 years: stood at $58.6 million in 2021, then gained by 10.06% to $64.5 million in 2022, then soared by 55.15% to $100.1 million in 2023, then gained by 21.7% to $121.8 million in 2024, then climbed by 25.75% to $153.2 million in 2025.
- The last three Non-Current Assets figures came in at $153.2 million (Q4 2025), $147.4 million (Q3 2025), and $146.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | 157.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 157.14 Mn |
| Dec 31, 2025 | 153.15 Mn |
| Sep 30, 2025 | 147.37 Mn |
| Jun 30, 2025 | 146.73 Mn |
| Mar 31, 2025 | 130.57 Mn |
| Dec 31, 2024 | 121.80 Mn |
| Sep 30, 2024 | 109.38 Mn |
| Jun 30, 2024 | 95.02 Mn |
| Mar 31, 2024 | 97.14 Mn |
| Dec 31, 2023 | 100.08 Mn |
| Sep 30, 2023 | 97.72 Mn |
| Jun 30, 2023 | 95.63 Mn |
| Mar 31, 2023 | 66.09 Mn |
| Dec 31, 2022 | 64.50 Mn |
| Sep 30, 2022 | 51.52 Mn |
| Jun 30, 2022 | 55.02 Mn |
| Mar 31, 2022 | 54.53 Mn |
| Dec 31, 2021 | 58.61 Mn |
| Sep 30, 2021 | 2.51 Mn |
| Jun 30, 2021 | 2.76 Mn |